assay-list
pTau217 Biomarker Assay
Frontage introduces a new ultrasensitive assay for the quantitative determination of pTau217 in human plasma, serum, and cerebrospinal fluid (CSF), one of the most promising blood-based biomarkers of Alzheimer’s disease.
Resources to Consider
poster
AAIC 2025: Comparison of Plasma pTau217 Assays on Different Platforms
Plasma pTau217 was recently discovered as a prominent blood-based biomarker in the early d...
assay-list
Biomarkers Assay List – July 2025
Frontage offers an impressive list of biomarker assays. Download our ever-growing list of ...
ebook
Sequencing Assays for Biomarker Discovery and Pharmacodynamics in...
In this eBook, we navigate the landscape of biomarker discovery through genomic profiling,...
webinar
Biomarker and Alzheimer’s disease: role of high sensitivity...
It has been said that the diagnosis of Alzheimer's disease enters the era of biomarkers. T...
poster
A Novel LC-MS/MS Assay for Quantifying Dermatan Sulfate as a...
Accumulation of dermatan sulfate (DS) in tissue and body fluid leads to mucopolysaccharido...
journal
Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of...
This Phase 1 proof‑of‑principle study shows that combining Vigil (a personalized tum...
fact-sheet
Biomarkers in Alzheimer’s Disease
Frontage’s Bioanalytical Team is highly experienced in developing, qualifying, and valid...
webinar
Companion Diagnostic Biomarkers: Importance, Trend, and Forecast
A companion diagnostic is a predictive biomarker test, utilized to support dosing decision...
panel-discussion
The Importance of Biomarker Discovery and Personalized Medicine
As more and more platforms and instruments come to play in the biomarker research, the met...
expert-interview
Analyzing Biomarkers in Drug Development
Biomarkers as indicators of biological and pathogenic processes have been used for decades...
fact-sheet
Bioanalytical Biomarkers
Frontage’s Bioanalytical Team is highly experienced in developing, qualifying and valida...
